Angiotensin receptor blockers (ARBs) and telmisartan have a renoprotective effect on renal endothelial function, preventing progression from microalbuminuria to macroalbuminuria, slowing the decline in glomerular filtration rate, and reducing proteinuria in overt nephropathy. ARB/ACEi combination therapy with SGLT2 inhibitors could achieve better control of blood pressure and estimated glomerular filtration rate. Combining SGLT2 with ACEi + ARB inhibitor reduced composite kidney outcome among T2DM patients with CKD. RSSDI guidelines provide comprehensive recommendations for managing hypertension in patients with diabetes. Non-pharmacological and pharmacological management of hypertension in diabetic patients are recommended, with ARBs, CCBs, ACE inhibitors, and beta-blockers often needed to achieve blood pressure goals.
